Sichuan Kelun Pharmaceutical: Announcement on the subsidiary's core product, lucan satuzumab (sAC-TMT), announcing research results at the 2024 American Society of Clinical Oncology Annual Meeting
Sichuan Kelun Pharmaceutical: Announcement on applying for liability insurance for company directors, supervisors and senior management
Sichuan Kelun Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Sichuan Kelun Pharmaceutical: Legal Opinion of Colon Pharmaceuticals 2023 Annual General Meeting of Shareholders
Sichuan Kelun Pharmaceutical: Announcement on the results of the election of the company's employee representatives and supervisors for a new term
Sichuan Kelun Pharmaceutical: Announcement on the subscription for domestic shares issued by the holding subsidiary Collumbotai
Colon Pharmaceuticals: Internal Control Self-Assessment Report
Colon Pharmaceutical: Report on the fiduciary management affairs of the public issuance of convertible corporate bonds by Sichuan Colon Pharmaceutical Co., Ltd. (2023)
Colon Pharmaceuticals: Shareholder Return Plan for the Next Three Years (2024-2026)
Colon Pharmaceuticals: Notice of Annual General Meeting of Shareholders
Colon Pharmaceuticals: Announcement on preparation for impairment of assets accrued for 2023
Colon Pharmaceuticals: Announcement on re-validation and extension of some fund-raising projects
Colon Pharmaceuticals: Announcement on changes in the company's registered capital and amendments to the company's articles of association
Colon Pharmaceuticals: Announcement on Using Own Funds to Purchase Wealth Management Products
Colon Pharmaceutical: Changjiang Securities Underwriting and Sponsorship Co., Ltd. summary report on the continuous supervision and sponsorship of the public issuance of convertible corporate bonds by Sichuan Kelun Pharmaceutical Co., Ltd.
Colon Pharmaceutical: Announcement on the 2023 salary situation and 2024 salary plan for the company's senior management
Colon Pharmaceuticals: Announcement on the redemption results of the “Colon Bond-to-Bond”
Colon Pharmaceuticals: Announcement on delisting of “Colon Bond-to-Bond”
Colon Pharmaceuticals: Announcement on the publication of research results on the subsidiary's core product, lukansastuzumab (Sac-TMT), at the 2024 American Association for Cancer Research Annual Meeting
Colon Pharmaceuticals: Announcement on convertible debt-for-equity swaps in the first quarter of 2024
No Data